Table 3.
Demographic and clinical details of 530 patients with iAMP21-positive ALL
| No. | Percent | |
|---|---|---|
| Total number | 530 | 100% |
| Sex | ||
| Female | 271 | 51% |
| Male | 255 | 48% |
| Unknown | 4 | 1% |
| Age (years)a | ||
| Mean | 10 | |
| Median | 9 | |
| Range | 2–30 | |
| <10 years, n (%) | 245 | 50% |
| >10 years, n (%) | 242 | 50% |
| White cell count (× 109/l)b | ||
| Mean | 17.1 | |
| Median | 5 | |
| Range | 0.3–900 | |
| <20 × 109/l | 384 | 83% |
| 20–50 × 109/l | 43 | 9% |
| >50 × 109/l | 31 | 7% |
| NCI risk statusc | ||
| Standard | 211 | 48% |
| High | 232 | 52% |
| Complete remissiond | ||
| Yes | 280 | 99% |
| <35 days | 214 | 76% |
| ≥35 days | 66 | 24% |
| Relapsed | ||
| Total patients | 90 | 32% |
| Site of relapse | ||
| Bone marrow | 56 | 62% |
| Isolated CNS | 20 | 22% |
| Combined | 10 | 11% |
| Other | 4 | 4% |
| Time to relapse | ||
| <18 months | 13 | 14% |
| 18 month to 3 years | 38 | 42% |
| 3–4 years | 21 | 23% |
| 4–5 years | 11 | 12% |
| 5 + years | 7 | 8% |
| Deathd | ||
| Total patients | 47 | 17% |
| Post relapse | 40 | 85% |
| In first CR | 5 | 11% |
| Nonremitters | 2 | 4% |
| Treatment schedulee | ||
| High risk | 121 | 43% |
| Standard risk | 158 | 57% |
Abbreviations: ALL, acute lymphoblastic leukaemia; CNS, central nervous system; CR, complete remission; iAMP21, intrachromosomal amplification of chromosome 21; NCI, National Cancer Institute.
a
Age available for 493 patients.
b
White cell count (WCC) available for 458 patients.
c
NCI risk status available for 443 patients.
d
Outcome data were assessed for 283 patients.
e
Treatment schedule was known for 279 patients.